Evidence map›Paper›PMID 32838223›Full record

ArticleJournal of the American College of Clinical Pharmacy : JACCP2020

COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective.

Kerry K Pickworth, Danielle Blais, Aaron Bagnola, Robert Barcelona, J Michael Boyd, Heidi Brink, Maya Chilbert, Daniel Galipeau, Brooke Gengler, Anthony T Gerlach and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American College of Clinical Pharmacy : JACCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Global contributions of pharmacists during the COVID-19 pandemic.Journal of the American College of Clinical Pharmacy : JACCP · 2020
    Article
  5. COVID-19 pandemic: Challenges and solutions from the cardiology pharmacist's perspective.Journal of the American College of Clinical Pharmacy : JACCP · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 1 country.

Kerry K PickworthThe Ohio State University Wexner Medical Center Columbus OH USA.ORCID https://orcid.org/0000-0003-4217-7261
Danielle BlaisThe Ohio State University Wexner Medical Center Columbus OH USA.
Aaron BagnolaInova Fairfax Medical Campus Falls Creek VA USA.ORCID https://orcid.org/0000-0001-6538-2781
Robert BarcelonaUniversity Hospitals Cleveland Medical Center Cleveland OH USA.
J Michael BoydThe Ohio State University Wexner Medical Center Columbus OH USA.ORCID https://orcid.org/0000-0001-9427-0156
Heidi BrinkUniversity of Nebraska Medical Center Omaha NE USA.
Maya ChilbertUniversity at Buffalo School of Pharmacy and Pharmaceutical Sciences Buffalo NY USA.
Daniel GalipeauThe Ohio State University Wexner Medical Center Columbus OH USA.
Brooke GenglerSSM Health St Louis University Hospital St Louis MO USA.
Anthony T GerlachThe Ohio State University Wexner Medical Center Columbus OH USA.ORCID https://orcid.org/0000-0001-5631-4218
Charles HayesSaint Luke's Hospital of Kansas City Kansas City MO USA.
Joshua JacobsUniversity of Utah Health Salt Lake City UT USA.ORCID https://orcid.org/0000-0002-9621-9060
Hasan KazmiCarilion Roanoke Memorial Hospital Roanoke VA USA.
Rachel LavelleThe Ohio State University Wexner Medical Center Columbus OH USA.
John LindsleyJohns Hopkins Hospital Baltimore MD USA.
Tracy E MacaulayUniversity of Kentucky College of Pharmacy Lexington KY USA.
Michael A MilitelloCleveland Clinic Cleveland OH USA.
Libby OrzelThe Ohio State University Wexner Medical Center Columbus OH USA.
Sajni PatelUniversity of Chicago Medical Center Chicago IL USA.ORCID https://orcid.org/0000-0003-2277-9564
Pamela SimoneUniversity of Chicago Medical Center Chicago IL USA.ORCID https://orcid.org/0000-0003-1070-0740
Kristen TascaCedars-Sinai Medical Center Los Angeles CA USA.
Sara VarnadoIntermountain Healthcare Utah Murray UT USA.
Sara ZoubekThe University of Kansas Health System Kansas City KS USA.
The Ohio State University Wexner Medical Center · USUniversity of Chicago Medical Center · USCarilion Roanoke Memorial Hospital · USCedars-Sinai Medical Center · USCleveland Clinic · USInova Fairfax Hospital · USIntermountain Healthcare · USJohns Hopkins Hospital · USSaint Louis University Hospital · USSaint Luke's Hospital · USUniversity at Buffalo, State University of New York · USUniversity Hospitals of Cleveland · USUniversity of Kansas · USUniversity of Kentucky · USUniversity of Nebraska Medical Center · USUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenges pharmacists worldwide. Alongside other specialized pharmacists, we re-evaluated daily processes and therapies used to treat COVID-19 patients within our institutions from a cardiovascular perspective and share what we have learned. To develop a collaborative approach for cardiology issues and concerns in the care of confirmed or suspected COVID-19 patients by drawing on the experiences of cardiology pharmacists across the country. On March 26, 2020, a conference call was convened composed of 24 cardiology residency-trained pharmacists (23 actively practicing in cardiology and 1 in critical care) from 16 institutions across the United States to discuss cardiology issues each have encountered with COVID-19 patients. Discussion centered around providing optimal pharmaceutical care while limiting staff exposure. The collaborative of pharmacists found for the ST-elevation myocardial infarction patient, many institutions were diverting COVID-19 rule-out patients to their Emergency Department (ED). Thrombolytics are an alternative to percutaneous coronary intervention (PCI) allowing for timely treatment of patients and decreased staff exposure. An emergency response grab and go kit includes initial drugs and airway equipment so the patient can be treated and the cart can be left outside the room. Cardiology pharmacists have developed policies and procedures to address monitoring of QT prolonging medications, the use of inhaled prostacyclins, and national drug shortages. Technology has allowed us to practice social distancing, while staying in close contact with our teams, patients, and colleagues and continuing to teach. Residents are engaged in unique decision-making processes with their preceptors and assist as pharmacist extenders. Cardiology pharmacists are in a unique position to work with other pharmacists and health care professionals to implement safe and effective practice changes during the COVID-19 pandemic. Ongoing monitoring and adjustments are necessary in rapidly changing times.

Indexed as

arrhythmiacardiologyCOVID‐19myocardial infarctionpharmacists

Identifiers

PMID32838223
PMCPMC7404851
OpenAlexW3043305116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.